Back to top
more

Cardinal Health (CAH)

(Real Time Quote from BATS)

$100.61 USD

100.61
705,662

-0.06 (-0.06%)

Updated Aug 12, 2024 03:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 20% (200 out of 250)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

PacBio (PACB) Q4 Earnings Beat, Adjusted Gross Margin Down

PacBio (PACB) witnesses strong revenue growth in the fourth quarter, partly aided by customers' continued product transition to the Revio system.

AMN Healthcare (AMN) Q4 Earnings and Revenues Beat Estimates

AMN Healthcare's (AMN) dismal results in the majority of its segments led to a soft overall fourth-quarter performance.

ResMed (RMD) to Treat Sleep Apnea With New AirCurve 11 (Revised)

ResMed's (RMD) new AirCurve11 series incorporates MyAir and AirView digital health apps to provide maximum comfort and support during therapy.

Shockwave Medical (SWAV) Q4 Earnings Beat, Revenues Rise Y/Y

Shockwave Medical's (SWAV) fourth-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.

Bio-Rad (BIO) Q4 Earnings Beat, Revenues Miss, Margins Down

Bio-Rad (BIO) continues to experience weak demand for Life Science products in China.

Here's Why You Should Retain Insulet (PODD) Stock for Now

The huge success of Omnipod 5 boosts investors' confidence in Insulet (PODD).

West Pharmaceutical (WST) Beats on Q4 Earnings, HVP Drives Sales

West Pharmaceutical's (WST) fourth-quarter results reflect a strong demand for non-COVID-19 products, especially HVP devices.

Labcorp (LH) Q4 Earnings and Revenues Beat, Margins Fall

Strength in Diagnostics Laboratories and Biopharma Laboratory Services businesses contributes to Labcorp's (LH) Q4 performance.

Here's Why You Should Retain IDEXX (IDXX) Stock for Now

Investors are optimistic about IDEXX (IDXX) growth in CAG business and strong global performance

Avantor (AVTR) Q4 Earnings & Revenues Top Estimates, Margins Down

Despite Avantor's (AVTR) continued stability in end markets, it reports an overall soft fourth-quarter performance.

Quest Diagnostics (DGX) Boosts Oncology Portfolio With New Test

Quest Diagnostics (DGX) debuts the MelaNodal Predict test in collaboration with SkylineDx.

Here's Why You Should Retain CVS Health (CVS) Stock for Now

Investors are optimistic about CVS Health (CVS) on its strong segmental performance and impressive restructuring plan.

Bruker (BRKR) Q4 Earnings Surpass Estimates, Margins Down

Strength in BioSpin and CALID groups contributes to Bruker's (BRKR) Q4 revenues.

Charles River (CRL) Q4 Earnings Surpass, Margins Contract

Charles River (CRL) delivers better-than-expected revenues and earnings in the fourth quarter of 2023.

DaVita (DVA) Q4 Earnings & Revenues Top Estimates, Margins Up

DaVita's (DVA) robust segmental revenues drive its fourth-quarter performance.

Ecolab (ECL) Q4 Earnings Surpass Estimates, Margins Rise

Ecolab's (ECL) robust performance across the majority of its segments drives its fourth-quarter sales despite business challenges.

Here's Why You Should Retain Charles River (CRL) Stock Now

Charles River's (CRL) share price is likely to grow, backed by the strength of the RMS segment.

Quest Diagnostics (DGX) Debuts PFAS Blood Test Offering

Quest Diagnostics (DGX) introduces the first consumer-initiated blood test with physician consult on questhealth.com.

Is Cardinal (CAH) a Solid Growth Stock? 3 Reasons to Think "Yes"

Cardinal (CAH) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Reasons to Retain The Cooper Companies (COO) in Your Portfolio Now

The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is concerning.

Omnicell (OMCL) Q4 Earnings Top Estimates, Gross Margin Down

Omnicell's (OMCL) fourth-quarter 2023 performance favorably reflects a heightened focus on managing costs.

DexCom (DXCM) Beats on Q4 Earnings, Strong CGM Demand Continues

DexCom's (DXCM) fourth-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.

Prestige Consumer (PBH) Q3 Earnings Top, Gross Margin Expands

Prestige Consumer's (PBH) third-quarter fiscal 2024 results reflect the power of a well-positioned and diversified portfolio.

Illumina (ILMN) Q4 Earnings Surpass Estimates, Margin Down

Illumina (ILMN) Q4 revenues increase year over year, driven by NovaSeq X instrument and consumables sales.

Baxter's (BAX) Q4 Earnings Top, Sales Rise on Strong Demand

Baxter (BAX) reports better-than-expected fourth-quarter earnings and sales. BAX's fourth-quarter and full-year results reflect solid demand for a range of its medically essential products.